Mesoblast Limited

Channel 10 News - 3 June 2005

Transcript

NEWSREADER :

World first research could slash recovery time for some broken bones and other medical conditions. And the Melbourne-based scientists say the technology may even revolutionise injury treatment for elite athletes.

REPORTER :

A horrific injury that could end a lucrative and blossoming career. Both bones in Nathan Brown's legs snapped, meaning he'll be out of footy indefinitely. Researchers say new stem cell technology could reduce recovery time for some fractures by as much as 50 per cent, even suggesting players bank stem cells as a biological insurance policy.

PROFESSOR SILVIU ITESCU, MESOBLAST :

If this athlete had a very severe, traumatic injury that potentially could be career threatening, you'd have these cells ready and available to be inserted directly into that fracture site.

REPORTER :

Brown's fracture is healing well of its own accord, but Professor Itescu says it's precisely the type of injury that could benefit.

ITESCU :

We then can have a million-fold increase in these type of cells and accelerate and repair the bone fracture.

REPORTER :

But applications for the research extend far beyond broken bones and elite athletes. Regeneration of soft tissues and even heart muscles will feature in the first clinical trials over the next few weeks.

DR RODNEY DILLEY – RESEARCH SCIENTIST :

People with intervertebral disc injuries can get repaired. People with arthritis and severe articular cartilage damage can get repaired.

REPORTER :

As well as the medical benefits, the research could open the door to a largely untapped, multi-billion dollar market.

 

END OF SEGMENT

 

 

For further information, please call:

Julie Meldrum
Mesoblast Limited
0419 228 128
julie.meldrum@mesoblast.com

>>back to What They Say

 

 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine